ProQR makes progress with potential treatment for LCA
Despite the challenges of the pandemic, researchers and pharmaceutical companies are still making progress towards delivering new treatments for inherited sight loss.
Search
Search results
Involving our community
Our community is informed and knowledgeable about current research projects into the cause(s) of and treatments for these conditions.
ProQR clinical trial for Leber’s Congenital Amourosis (LCA) 10
Biopharmaceutical company ProQR is conducting a Phase 2/3 clinical trial (Illuminate) to measure the safety and effectiveness of RNA therapy, Sepofarsen which aims to treat Leber's Congenital Amourosis (LCA) 10.
Look Forward – Winter 2022 – Issue 178
The cover of this edition celebrates the success of our amazing London Marathon team. Together they have raised more than £43,000.
Diagnosis and beyond
Making yourself aware of the what you are entitled to, and understanding the diagnosis pathway for inherited sight loss, will put you in a stronger position to seek better support.
Inheritance patterns
Your doctor or genetic counsellor will spend some time asking about other people in your family to try to work out the way in which your particular faulty gene has been passed down through the generations – this is referred to as the inheritance pattern.
e-Newsletter April 2024
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.
Look Forward – Winter 2023 – Issue 181
Inside this edition, register now for our AI webinar on 7 December with Dr Nikolas Pontikos.
e-Newsletter February 2024
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.